NOCIL Ltd Q2 FY2026 Concall Summary & Transcript Notes

Source transcript PDF: https://www.stockscans.in/document/viqrnwsqcvi3v97qxubjnite.pdf

# 1. Financial Performance

## A. Key Figures
   *   **Net Revenue:** **₹321 Cr** Q2 FY'26 (-4.5% QoQ) · **₹657 Cr** H1 FY'26 (-10.6% YoY)
   *   **Operating EBITDA:** **₹22 Cr** Q2 FY'26 (7%) · **₹53 Cr** H1 FY'26 (1%) (-33% YoY)
   *   **Operating PBT:** **₹19 Cr** Q2 FY'26 · **₹42 Cr** H1 FY'26 (-39% YoY)
   *   **PAT:** **₹29 Cr** H1 FY'26 (-58% YoY)

## B. Revenue Trends
   *   **Pricing Pressure Dominates:** Revenue decline driven by **competitive import-led pricing pressure**, only partially offset by lower raw material costs.
   *   **Sequential Volume Stability:** Despite lower prices, sequential revenue drop was contained, suggesting **resilient volume performance** amid challenging market conditions.

## C. Profit Margins
   *   **Margin Compression Intensifies:** EBITDA and PBT margins contracted significantly YoY, reflecting both **top-line pressure** and absence of prior-year tax benefits.
   *   **Prior-Year Tax Benefit Skews Comparison:** H1 FY'25 PAT included a **₹15 Cr deferred tax credit** from LTCG rate remeasurement, creating a difficult base for YoY earnings comparison.

## D. Cash Flow Health
   *   **Working Capital Discipline:** Operating cash flow improved due to **focused optimization of working capital**, supporting liquidity despite weak earnings.

## E. Balance Sheet Position
   *   **Net Cash Maintained:** Company retains a **net cash position** and has **shortened working capital cycle**, providing resilience amid soft demand outlook.
   *   **North America Headwinds:** CV OEM demand in North America expected to remain weak until **mid-2026**, prolonging sectoral challenges.
   *   **Dumping Duty Uncertainty:** Management refrains from comment on anti-dumping case, citing **sub judice status**; awaits DGTR final recommendations.

---

# 2. Volume & Market Share

## A. Key Figures
   *   **Q2 FY'26 Sales Volume:** **138** (Q1 FY'20 = 100)
   *   **Volume Split:** **~67% domestic** · **~33% exports**
   *   **Domestic Market Size:** **80,000–85,000 tons/year**
   *   **Market Share:** **38–40%** (domestic rubber chemicals)

## B. Domestic Volumes
   *   **Resilient Sequential Growth:** Domestic volumes posted strong quarter-on-quarter expansion despite macro headwinds, including GST 0 rollout and global dumping pressures.
   *   **Recovery Trajectory:** Management expects full-year volume growth despite H1 decline, supported by improving domestic demand dynamics and GST-related tailwinds.
   *   **Latex Volume Reset:** Current latex volumes remain significantly below peak pandemic levels, reflecting structural demand shifts.

## C. Export Volumes
   *   **Near-Term Export Pressure:** Export volumes declined due to U.S. tariff disruptions and cautious buyer behavior, with choppy conditions expected to persist in the short term.
   *   **D. S. Market Engagement:** NOCIL continues shipping to the U.S. amid active dialogue to navigate trade barriers and stabilize export flows.

## D. Market Share Trends
   *   **Stable Competitive Position:** NOCIL maintains a consistent ~40% domestic market share, with no evidence of material erosion despite competitive intensity.
   *   **Favorable Domestic Outlook:** Robust tire industry fundamentals, driven by infrastructure spending and reduced GST rates, support sustained demand for rubber chemicals.

---

# 3. Product & Segment Performance

## A. Key Figures
   *   **Latex Sales Mix:** **~8%** of total sales volume

## B. Latex Business
   *   **Volume Decline:** Latex segment experienced YoY volume contraction in Q2, driven by **tariff uncertainties** in key markets, now resolving.
   *   **Cyclical Context:** Current softness follows a relatively strong prior year, which itself rebounded from post-COVID lows, indicating a near-term cyclical dip.
   *   **Strategic Positioning:** Latex products are **functionally unique** and not directly comparable to peers; relationships are long-duration once secured.

## C. Rubber Chemicals
   *   **Competitive Edge:** Broader product portfolio enhances competitiveness versus Korean suppliers, who offer only **a single antioxidant product**, limiting their market reach despite lower prices.

## D. New Product Launches
   *   **Launch Timeline:** New products are in **soft launch phase**, with commercial sales expected before end-FY26, though initial volumes will be constrained.
   *   **Growth Pathway:** Management anticipates new offerings could become **substantial contributors** within 2–3 years, contingent on customer approvals and capacity scaling.

---

# 4. Manufacturing & Utilization

## A. Key Figures
   *   **Capacity Utilization:** ~65% current rate (10-year low in operating leverage)
   *   **Working Capital Efficiency:** **20% improvement** in sales days efficiency

## B. Capacity Expansion
   *   **TDQ Expansion on Schedule:** Dahej TDQ capacity expansion remains on track for commissioning and trial production in H1 2026.

## C. Utilization Rates
   *   **Suboptimal Utilization Weighs on Leverage:** Current ~65% capacity utilization constrains fixed cost absorption, resulting in the weakest operating leverage benefits in a decade.

## D. Cost Efficiency
   *   **Margin Resilience via Operational Levers:** Management is countering margin pressure through pricing, volume growth, and **multiple cost optimization initiatives** yielding near-term savings.
   *   **Efficiency Gains Taking Hold:** Improvements in inventory management, production planning, and raw material handling are already reducing **per-kilo costs**, **power/fuel consumption**, and **conversion costs**.
   *   **Conversion Cost Outlook:** Structural declines expected from Q4 FY'26 onward, though magnitude remains uncertain due to inflation and performance variability.

---

# 5. Trade & Supply Chain

## A. Key Figures
   *   **Imported Intermediate Usage:** **30%** of Indian finished product demand relies on imported penultimate intermediate from **China and EU**
   *   **Inventory Resolution:** **90% to over 95%** of high-cost inventory issue resolved
   *   **Procurement Lead Time:** **60–70 days** advance planning required due to import dependence
   *   **B. S. Market Share:** **~9%** of global rubber chemicals demand

## B. Import Dependence
   *   **Structural Vulnerability:** Most domestic producers remain exposed to foreign supply chains due to reliance on imported intermediates, creating logistical and pricing risks.
   *   **Operational Constraint:** Extended procurement timelines—nearly 10-week lead times—highlight ongoing challenges in supply chain agility versus fully domestic models.

## C. Anti-dumping Filings
   *   **Active Trade Remedies:** Antidumping petitions on key rubber chemical products accepted for investigation, with **positive engagement under DGTR rules** and reasonable confidence in favorable outcomes.
   *   **Strategic Impact:** If implemented, duties could **curb Chinese import competitiveness**, supporting both pricing power and volume recovery, independent of FTA exemptions for countries like Korea.
   *   **Execution Risk:** Despite DGTR recommendations on Chinese dumping, final duty imposition awaits **Finance Ministry approval**, introducing uncertainty amid broader diplomatic considerations.

## D. Global Supply Shifts
   *   **Regional Demand Divergence:** Western markets remain weak, while Europe shows mild rebound on pre-emptive import activity; U.S. exports face **temporary tariff headwinds** but long-term solutions in progress.
   *   **Competitive Positioning:** NOCIL differentiating via **supply reliability** and potential overseas stock points to retain customers despite pricing pressure.
   *   **Emerging Rivalry:** Korea gaining share in select segments due to **lower tariff advantages** over China and India, altering competitive dynamics.

---

# 6. Pricing & Competitive Risks

## A. Import Pricing Pressure
   *   **Headline:** U.S. OE demand softens amid tariff uncertainties, while replacement demand holds steady, weighing on industry performance.
   *   **Headline:** Korean exporters gaining share in antioxidants via **aggressive pricing below Chinese levels**, supported by India-Korea FTA advantages.
   *   **Headline:** Tariffs have not reshaped market shares meaningfully, as **Europe retains dominance in U.S. supply** due to entrenched operations and trade dynamics.
   *   **Headline:** Despite China facing **25% higher tariffs than India**, Indian suppliers have only achieved marginal cost competitiveness, limiting pricing leverage.
   *   **Headline:** Landed cost—including tariff absorption—is decisive for U.S. procurement, making duty status a key gatekeeper for market participation.

## B. Competitor Behavior
   *   **Headline:** NOCIL’s long-term customer relationships provide resilience against intense competition and predatory pricing tactics.
   *   **Headline:** Market benchmarks distorted by **opportunistic and situational pricing**, creating perception of unrealistically low prices.
   *   **Headline:** Speculation persists that some rivals may benefit from **external or government support**, enabling economically unsustainable pricing.
   *   **Headline:** Indian producers are broadly cost-competitive vs. West, though delivered costs were previously **5–6% above Europe**, narrowing under current conditions.

---

# 7. Guidance & Outlook
  
## A. Key Figures
   *   **Capex (Dahej Expansion):** **₹250 Cr** project (~75–80% complete) · Trial production expected H1 CY'26 (Jan–Jun 2026)

## B. Volume Projections
   *   **Long-Term Volume Strategy:** Growth trajectory remains intact with active customer penetration and market expansion, independent of antidumping duty (ADD) outcome.

## C. Margin Recovery
   *   **Sustained Efficiency & Leverage:** Management expects current efficiency levels to persist in H2, with operating leverage improving as volumes rise.  
   *   **Margin Improvement Pathway:** Sequential profit improvement anticipated from incremental efficiency measures, though timing remains unspecified.  
   *   **Resilient Outlook:** Despite pricing pressure, NOCIL views current conditions as the "new normal" and remains positive on FY'27 growth.

## D. Capex Timeline
   *   **Dahej Expansion on Track:** Trial runs set for H1 CY'26, with incremental commercial production expected by **mid-2026**.